Obesity medicines reduced weight, while other reported benefits differed
A network meta-analysis found greater weight loss than placebo across the assessed medicines, but the abstract provides limited detail on other outcomes and safety.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
All assessed obesity medicines produced significantly greater weight loss than placebo at study end. The abstract also reports different benefits for selected obesity-related conditions, depending on the medicine. Those findings do not identify a universally best option: detailed comparisons, patient subgroups and safety results are needed to understand the balance for particular patients.
This abstract-based summary has no adverse-event results to assess, although safety was reviewed. Several clinical benefits are named without effect sizes or subgroup details, limiting interpretation of benefits and risks.
What researchers found
Total body weight loss, measured as a percentage
Each assessed obesity medication versus placebo at study end; individual trial lengths were not given.
Weight was the main endpoint
The main outcome was the percentage of total body weight lost. Researchers also considered metabolic measures, quality of life, serious adverse events, cardiovascular outcomes and remission of obesity-related conditions as distinct endpoints.
Other outcomes require context
The abstract reports fewer major cardiovascular events with semaglutide and remission of obstructive sleep apnea with tirzepatide. It does not identify the relevant patient subgroups or give effect sizes for these outcomes.
The original publication
A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults.
McGowan B, Ciudin A, Baker JL et al.
Nat Med · 2025
- PubMed ID
- 41039116
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.